Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2009, Vol. 3 Issue (4) : 443-446     DOI: 10.1007/s11684-009-0079-5
Research articles |
Effect of atorvastatin on tumor growth and metastasis in a breast cancer cell xenograft model and its mechanism
Liu LIU MD, PhD1,Yaogui NING MM2,Chen CHEN MD2,Daowen WANG MD, PhD2,
1.Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; 2.Department of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China;
Download: PDF(109 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  This paper aims to evaluate the effects and the possible mechanisms of atorvastatin on tumor growth and metastasis in a xenograft tumor model. Twenty-four female athymic BALB/C mice with MDA-MB-435 xenograft tumors were randomly assigned to three groups: a control group, a low-dose atorvastatin treatment group, and a high-dose atorvastatin treatment group. The mice in the treatment groups began to be administered with atorvastatin (10 or 20 mg/kg per day) when the xenograft tumors reached 1 cm in diameter. At the end of the experiment, the tumor volume and weight and the lung metastasis colonies of each mouse were measured. Western blotting was applied to detect phosphorylation of protein kinase B (PKB, Akt), extracellular signal regulated kinase (ERK), c-Jun N-terminal Kinase (JNK), and the expression of cytochrome P450 (CYP) subtype CYP2J2. Atorvastatin suppressed xenograft tumor growth and metastasis both in the low-dose and the high-dose treatment groups (P < 0.05). Atorvastatin also decreased the phosphorylated Akt (p-Akt) and p-ERK but increased p-JNK expression. However, atorvastatin did not alter the expression of CYP2J2 in tumor tissue. This suggests that atorvastatin has the efficacy of suppressing tumor growth and metastasis in vivo. These effects were not dependent on down-regulation of CYP2J2 expression.
Keywords atorvastatin      xenograft tumor      metastasis      CYP2J2      
Issue Date: 05 December 2009
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0079-5     OR     http://academic.hep.com.cn/fmd/EN/Y2009/V3/I4/443
Harris R E, Alshafie G A, Abou-Issa H, Seibert K. Chemopreventionof breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res, 2000, 60(8): 2101―2103
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M J. Cancer statistics, 2003. CACancer J Clin, 2003, 53(1): 5―26

doi: 10.3322/canjclin.53.1.5
Athyros V G, Kakafika A I, Tziomalos K, Karagiannis A, Mikhailidis D P. Pleiotropic effects of statins–clinicalevidence. Curr Pharm Des, 2009, 15(5): 479―489

doi: 10.2174/138161209787315729
Kuoppala J, Lamminpää A, Pukkala E. Statins and cancer: A systematicreview and meta-analysis. Eur J Cancer, 2008, 44(15): 2122―2132

doi: 10.1016/j.ejca.2008.06.025
Jiang J G, Chen C L, Card J W, Yang S, Chen J X, Fu X N, Ning Y G, Xiao X, Zeldin D C, Wang D W. Cytochrome P450 2J2 promotesthe neoplastic phenotype of carcinoma cells and is up-regulated inhuman tumors. Cancer Res, 2005, 65(11): 4707―4715

doi: 10.1158/0008-5472.CAN-04-4173
Jiang J G, Ning Y G, Chen C, Ma D, Liu Z J, Yang S, Zhou J, Xiao X, Zhang X A, Edin M L, Card J W, Wang J, Zeldin D C, Wang D W. Cytochromep450 epoxygenase promotes human cancer metastasis. Cancer Res, 2007, 67(14): 6665―6674

doi: 10.1158/0008-5472.CAN-06-3643
Knopp R H. Drug treatment of lipid disorders. N EnglJ Med, 1999, 341(7): 498―511

doi: 10.1056/NEJM199908123410707
Davignon J. Beneficialcardiovascular pleiotropic effects of statins. Circulation, 2004, 109(23 Suppl 1): III39―43

doi: 10.1161/01.CIR.0000131517.20177.5a
Liao J K. Effects of statins on 3-Hydroxy-3-methyglutaryl coenzyme A reductaseinhibition beyond low-density lipoprotein cholesterol. Am J Cardiol, 2005, 96[5A]: 24F―33F

doi: 10.1016/j.amjcard.2005.06.009
Adam O, Neuberger H R, Böhm M, Laufs U. Preventionof atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme Areductase inhibitors. Circulation, 2008, 118(12): 1285―1293

doi: 10.1161/CIRCULATIONAHA.107.760892
Hall A. RhoGTPase and the actin cytoskeleton. Science, 1998, 279(5350): 509―514

doi: 10.1126/science.279.5350.509
Sahai E, Marshall C J. Rho-GTPases and cancer. Nat Rev Cancer, 2002, 2(2): 133―142

doi: 10.1038/nrc725
Garwood E R, Kumar A S, Baehner F L, Moore D H, Au A, Hylton N, Flowers C I, Garber J, Lesnikoski B A, Hwang E S, Olopade O, Port E R, Campbell M, Esserman L J. Fluvastatin reduces proliferation and increases apoptosis in womenwith high grade breast cancer. Breast CancerRes Treat, 2009Aug29. [Epub ahead of print]
Kang S, Kim E S, Moon A. Simvastatin and lovastatin inhibit breast cell invasioninduced by H-Ras. Oncol Rep, 2009, 21(5): 1317―1322
Mannello F, Tonti G A. Statins and breast cancer:may matrix metalloproteinase be the missing link. Cancer Invest, 2009, 27(4): 466―470

doi: 10.1080/07357900802491444
Sánchez C A, Rodríguez E, Varela E, Zapata E, Páez A, Massó F A, Montaño L F, Lóopez-Marure R. Statin-inducedinhibition of MCF-7 breast cancer cell proliferation is related tocell cycle arrest and apoptotic and necrotic cell death mediated byan enhanced oxidative stress. Cancer Invest, 2008, 26(7): 698―707

doi: 10.1080/07357900701874658
Herrero-Martin G, López-Rivas A. Statins activatea mitochondria-operated pathway of apoptosis in breast tumor cellsby a mechanism regulated by ErbB2 and dependent on the prenylationof proteins. FEBS Lett, 2008, 582(17): 2589―2594

doi: 10.1016/j.febslet.2008.06.034
Borgquist S, Djerbi S, Pontén F, Anagnostaki L, Goldman M, Gaber A, Manjer J, Landberg G, Jirström K. HMG-CoA reductase expression in breast cancer is associatedwith a less aggressive phenotype and influenced by anthropometricfactors. Int J Cancer, 2008, 123(5): 1146―1153

doi: 10.1002/ijc.23597
Campbell M J, Esserman L J, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar A S, Adduci K, Marx C, Petricoin E F, Liotta L A, Winters M, Benz S, Benz C C. Breast cancer growth prevention by statins. Cancer Res, 2006, 66(17): 8707―8714

doi: 10.1158/0008-5472.CAN-05-4061
Koyuturk M, Ersoz M, Altiok N. Simvastatin induces apoptosis in human breast cancercells: p53 and estrogen receptor independent pathway requiring signalingthrough JNK. Cancer Lett, 2007, 250(2): 220―228

doi: 10.1016/j.canlet.2006.10.009
Denoyelle C, Albanese P, Uzan G, Hong L, Vannier J P, Soria J, Soria C. Molecular mechanism of theanti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase,on aggressive human breast cancer cells. Cell Signal, 2003, 15(3): 327―338

doi: 10.1016/S0898-6568(02)00124-9
Zeldin D C. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem, 2001, 276(39): 36059―36062

doi: 10.1074/jbc.R100030200
[1] Chunxiao Li,Haijuan Wang,Feng Lin,Hui Li,Tao Wen,Haili Qian,Qimin Zhan. Bioinformatic exploration of MTA1-regulated gene networks in colon cancer[J]. Front. Med., 2016, 10(2): 178-182.
[2] Jiangnan Liu,Bin Yi,Zhe Zhang,Yi Cao. CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells and hepatocytes[J]. Front. Med., 2016, 10(2): 204-211.
[3] Felice Ho-Ching Tsang,Sandy Leung-Kuen Au,Lai Wei,Dorothy Ngo-Yin Fan,Joyce Man-Fong Lee,Carmen Chak-Lui Wong,Irene Oi-Lin Ng,Chun-Ming Wong. MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility[J]. Front. Med., 2015, 9(3): 331-343.
[4] Carmen Chak-Lui Wong, Alan Ka-Lun Kai, Irene Oi-Lin Ng. The impact of hypoxia in hepatocellular carcinoma metastasis[J]. Front Med, 2014, 8(1): 33-41.
[5] Lunxiu Qin. Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies[J]. Front Med, 2014, 8(1): 24-32.
[6] Tian Wang, Yan Li, Abidan Tuerhanjiang, Wenwen Wang, Zhangying Wu, Ming Yuan, Shixuan Wang. Correlation of Twist upregulation and senescence bypass during the progression and metastasis of cervical cancer[J]. Front Med, 2014, 8(1): 106-112.
[7] Dong KUANG, Guo-Ping WANG, . Hilar cholangiocarcinoma: Pathology and tumor biology[J]. Front. Med., 2010, 4(4): 371-377.
[8] Ling XU MM, Feng WANG MM, Xuan-Fu XU MD, Wen-Hui MO BM, Rong WAN MD, Chuan-Yong GUO MD, Xing-Peng WANG MD, . Data mining of microarray for differentially expressed genes in liver metastasis from gastric cancer[J]. Front. Med., 2010, 4(2): 247-253.
[9] Hongying ZHANG, Jianwu TANG, Wenting ZHU, Chunxiu HU, Guowang XU. Establishment and drug sensitivity evaluation of murine ascites hepatocarcinoma cell line with high lymphatic metastatic potential (Hca-P/L6)[J]. Front Med Chin, 2009, 3(2): 119-129.
[10] Yang YU, Jibin LIU, Lixue YIN. Application progress of lymphography in oncology[J]. Front Med Chin, 2009, 3(1): 13-19.
[11] QIN Lunxiu, TANG Zhaoyou, GUAN Xinyuan, YE Qinghai, JIA Huliang, REN Ning. The predictive value of chromosome 8p deletion for metastasis of hepatocellular carcinoma: a summary of works in 10 years[J]. Front. Med., 2008, 2(3): 211-215.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed